



Utilization *ALERT*

- Before using this MCP for evaluation of medical necessity, benefit coverage **MUST** be verified in the member's EOC or benefit document.
 - For District of Columbia (DC) situs members, please refer to the applicable benefit plan or state guidelines.
 - For Federal members, please refer to FEHBP brochure for benefit details.
 - For Maryland or Virginia Commercial, Medicare, and Medicaid members, please refer to the applicable benefit plan or state guidelines.
 - Please refer to CMS guidelines: National Coverage Determination (NCD) or Local Coverage Determination (LCD) for Medicare members. This MCP applies if no CMS criteria are available.
-

I. Internal & Outside Referral Guidelines

- A. Kaiser Foundation Health Plan (KFHP) provides Sexual Reassignment Surgery (SRS) for the treatment of patients with gender Incongruence to members who have the Transgender Surgery benefit and meet the medical criteria below. KFHP commits to following the World Professional Association for Transgender Health (WPATH) most up to date standards of care. Currently, we are following the World Professional Association for Transgender Health (WPATH) standards of care, 8th version, for covered services. Members who do not have the Gender affirming surgery benefit but wish to access these on a fee for service basis, will be evaluated according to the same medical criteria.
- B. Non-surgical services for labs, hormonal therapy, and mental health services are covered for transgender treatment under base benefits.
- C. All referrals require approval by the Gender Pathways Medical Lead.

II. Covered Sexual Reassignment Surgery Procedures

WPATH recommends these surgeries be considered if member experiences discomfort or distress that is caused by a discrepancy between the member's gender identity and his or her sex assigned at birth, including the associated gender role and/or primary and secondary sex characteristics.

A. Male-to-Female (MtF):

- Breast augmentation;
- Clitoroplasty;
- Labiaplasty;
- Orchiectomy;
- Penectomy;
- Tracheal shave;
- Vaginoplasty
- Facial Feminization

- B. Female-to-Male (FtM):**
- Glansplasty;
 - Hysterectomy;
 - Mastectomy with chest reconstruction;
 - Metoidioplasty;
 - Mons Resection;
 - Penile Prosthesis;
 - Phalloplasty;
 - Salpingo-Oophorectomy;
 - Scrotoplasty;
 - Testicular Prosthesis;
 - Urethroplasty;
 - Vaginectomy
 - Facial Masculinization

III. Genital Surgery Clinical Review Criteria

Members are eligible for genital surgery coverage, if they have the transgender surgery benefit, and meet all of the following criteria:

- A.** Member is at least 18 years old; **and** Gender Incongruence is marked and sustained such that:
1. Member experiences discomfort or distress that is caused by a discrepancy between a person's gender identity and that person's sex assigned at birth (and the associated gender role and/or primary and secondary sex characteristics); **and**
 2. Other possible causes of apparent gender incongruence have been identified and excluded; **and**
- B.** Member has the capacity to make fully informed decisions and to consent to treatment; **and**
- C.** If significant medical or mental health concerns are present, they are reasonably well controlled; **and**
- D.** Member has completed a program of gender incongruence evaluation and treatment, as described below. These criteria may also be accessed and replaced by the KPMAS Health Connect checklist which will remain in the member's electronic medical record.
1. Member has undergone or is in the process of completing 6 continuous months of hormone therapy as appropriate to the patient's gender goals (unless the patient has a medical contraindication or does not desire to take hormones); **and**
 2. Member has one evaluation letter recommending GCS from a qualified mental health professional who has independently assessed the patient. The referral should be from a



person who has only had an evaluative role with the patient. The referral letter is expected to cover the following recommended content:

- a. The member's general identifying characteristics;
 - b. Results of the member's psychosocial assessment, including any diagnoses;
 - c. The duration of the mental health professional's relationship with the Patient, including the type of evaluation and therapy or counseling to date;
 - d. An explanation that the criteria for surgery have been met, and a brief description of the clinical rationale for supporting the patient's request for surgery;
 - e. A statement about the fact that informed consent has been obtained from the patient;
 - f. As statement that the member understands the effect of gender-affirming surgical intervention on reproduction and they have explored fertility preservation options if so desired;
 - g. A statement that the mental health professional is available for coordination of care and welcomes a phone call to establish this; **and**
3. Member has had a mental health evaluation and a medical evaluation, which has deemed the patient to have no medical or psychological contraindications for surgery. Additionally, the care team has reviewed the selection of surgical procedures and has deemed them medically necessary.
 4. FtM members requesting metoidioplasty or phalloplasty and MtF members requesting vaginoplasty must also have undergone or be in the process of completing 12 continuous months of living in the identified gender role.

IV. Mastectomies with Chest Reconstruction Clinical Review Criteria

FtM members are eligible for mastectomies with chest reconstruction, if they have the transgender surgery benefit, and meet **all** of the following criteria:

- A. Member is at least 18 years old or 16 years and older with either parental consent or legal emancipation after ample time of living in the desired gender role; **and**
- B. Member has been diagnosed with Gender Incongruence that is marked and sustained such that:
 1. Member experiences discomfort or distress that is caused by a discrepancy between a person's gender identity and that person's sex assigned at birth (and the associated gender role and/or primary and secondary sex characteristics); **and**
 2. Other possible causes of apparent gender incongruence have been identified and excluded; **and**
- C. Member has the capacity to make fully informed decisions and to consent to treatment; **and**
- D. If significant medical or mental health concerns are present, they are well controlled; **and**
- E. Member has one letter of recommendation for breast/chest surgery from a qualified mental health professional who has independently assessed the patient. For providers working within a multidisciplinary specialty team, a letter may not be necessary; rather, the assessment and recommendation can be documented in the patient's chart. The referral is expected to cover the following recommended content:

1. The member's general identifying characteristics; and
 2. Results of the member's psychosocial assessment, including any diagnoses; and
 3. The duration of the mental health professional's relationship with the member, including the type of evaluation and therapy or counseling to date; and
 4. An explanation that the criteria for surgery have been met, and a brief description of the clinical rationale for supporting the patient's request for surgery; and
 5. A statement about the fact that informed consent has been obtained from the patient; and
 6. A statement that the mental health professional is available for coordination of care and welcomes a phone call to establish this; **and**
- F. Member has had a mental health evaluation and a medical evaluation, which has deemed the patient to have no medical or psychological contraindications for surgery.
- V. Male to Female Chest Surgery, Breast Augmentation Clinical Review Criteria**
- MtF members are eligible for Breast Augmentation and should meet **all** of the following criteria:
- A.** Member is at least 18 years old **except** for MtF members under the age of 18; chest surgery can be carried out on adolescents 16 years or older, after ample time of living in the identified gender role and after at least one year of estrogen treatment (unless hormonal therapy is contraindicated). Adolescent MtF patients seeking chest surgery must also have parental consent or be legally emancipated; and
- B.** Member has been diagnosed with Gender Incongruence that is marked and sustained such that:
1. Member experiences discomfort or distress that is caused by a discrepancy between a person's gender identity and that person's sex assigned at birth (and the associated gender role and/or primary and secondary sex characteristics); **and**
 2. Other possible causes of apparent gender incongruence have been identified and excluded; **and**
- C.** Member has the capacity to make fully informed decisions and to consent to treatment; **and**
- D.** If significant medical or mental health concerns are present, they are well controlled; **and**
- E.** Member has one letter of recommendation for breast/chest surgery from a qualified mental health professional who has independently assessed the patient. For providers working within a multidisciplinary specialty team, a letter may not be necessary; rather, the assessment and recommendation can be documented in the patient's chart. The referral is expected to cover the following recommended content:
- i. The member's general identifying characteristic;
 - ii. Results of the member's psychosocial assessment, including any diagnoses;
 - iii. The duration of the mental health professional's relationship with the member, including the type of evaluation and therapy or counseling to date;
 - iv. An explanation that the criteria for surgery have been met, and a brief description of the clinical rationale for supporting the patient's request for surgery;

- F. Surgical breast augmentation will be evaluated for coverage after 6 months of hormonal therapy; or, if the patient is unable to take hormones due to medical contraindications patient will be assessed by plastic/reconstructive surgeon for appropriate surgical intervention.

VI. Exclusions/Limitations

- A. The following procedures are excluded from transgender surgery coverage:
1. Lipoplasty of the waist;
 2. Electrolysis or laser hair removal, except for preparation of the perineum for surgery or facial hair removal when medically necessary;
 3. Tracheal Shave procedure (chondrolaryngoplasty) will be limited to members 18 years and older; and
 4. Gender affirming facial procedures require at least 12 months of Hormone Replacement Therapy (HRT) unless contraindicated or member declines
- B. Voice Modification surgery is excluded except for Maryland Medicaid members due to a Maryland state mandate beginning 1/2024. Approval for voice modification surgery requires:
1. 12 months of gender affirming voice and communication therapy specifically directed at authentic voice modification aligned with their gender **and**
 2. A recommendation from a licensed speech-language pathologist specializing in gender affirming voice services documenting that the member cannot attain the fundamental frequency level aligned with their gender without surgery.
- C. Coverage for infertility services, are determined in accordance with the member's KFHP infertility/fertility preservation benefits.

References

1. Adelson, SL Practice Parameter on Gay, Lesbian, or Bisexual Sexual Orientation, Gender Nonconformity, and Gender Discordance in Children and Adolescents *J Am Acad of Child & Adoles Psychiatry*. Sept 2012. 51:9: 957-74.
2. Burns, Christine. San Francisco Consensus Augurs Well for ICD Revision, *Just Plain Sense* (blog), 18 February 2013.
3. Coleman E, Bockting W, Botzer M. et al. Standards of Care for the Health of Transsexual, Transgender, and Gender Nonconforming People, 7th Version. The World Professional Association for Transgender Health (WPATH). *Int J of Transgenderism*. 2011. 13:165-232.
4. De Cuypere G, Knudson, G, Green J. WPATH Consensus Process Transgender and Transsexual Related Diagnoses in ICD 11. May 2014. *The World Professional Association for Transgender Health (WPATH)*.
5. Deutsch MB, Feldman JL Updated recommendations from the world professional association for transgender health standards of care. *Am Fam Physician* 15 Jan 2013; 87(2): 89-93.
6. Gorin-Lazard A., Is hormonal therapy associated with better quality of life in transsexuals? A cross-sectional study. *J Sex Med Feb* 2012; 9(2): 531-41.
7. Hembree WC, Cohen-Kettenis, P et al. Endocrine Treatment of Transsexual Persons: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrin & Metab*. Sep 2009; 94:9, 3132-54.



8. Hembree WC Guidelines for pubertal suspension and gender reassignment for transgender adolescents. *Child Adolesc Psychiatr Clin N Am* Oct 2011; 20(4): 725-32.
9. Motmans J, Meier P, et al. Female and male transgender quality of life: socioeconomic and medical differences. *J Sex Med* 01 Mar 2012; 9(3): 743-50.
10. Randall A Practice Parameter on Sexual Orientation, Gender Nonconformity, and Gender Identity Issues in Children and Adolescents. *Am Fam Physician*. 2013 Aug 1; 88(3): 202-5.
11. Rotondi NK, Bauer GR, et al. Nonprescribed hormone use and self-performed surgeries: "do-it-yourself" transitions in transgender communities in Ontario, Canada. *Am J Public Health* Oct 2013; 103(10): 1830-6.
12. Sills I. Increasing Expertise in Caring for the Gender Dysphoric Child and Transgender Adolescent_ Increasing Expertise in Caring for the Gender Dysphoric Child and Transgender Adolescent, *J Pediatrics*. Apr 2014; 164,(4): 689-90.
13. State of California Dept. of Insurance. Economic Impact Assessment Gender Nondiscrimination in Health Insurance. 13 Apr 2012.
14. U.S. Dept. of Health and Human Services. Invalidation of National Coverage Determination 140.3 – Transsexual Surgery. CMS. Effective 30 May 2014.
15. Wallien, MSC, Swaab H, Cohen-Kettenis PT. Psychiatric Comorbidity among Children with Gender Identity Disorder. *J Am Ac Child & Adoles Psy*. 46(10) Oct 2007: 1307-14.
16. Wilczynski C, Emanuele MA. Treating a transgender patient: overview of the guidelines. *Postgrad Med*. Nov 2014; 126 (7): 121-24.
17. Williamson C. Providing care to transgender persons: a clinical approach to primary care, hormones, and HIV management. *J Assoc Nurses AIDS Care* May 2010; 21(3): 221.
18. Wylie, K. Good practice guidelines for the assessment and treatment of adults with gender dysphoria. Royal College of Psychiatrists, London. Oct 2013.
19. Psychotherapists as gatekeepers: An evidence-based case study highlighting the role and process of letter writing for transgender clients. Budge SL, - *Psychotherapy (Chic)* - September 1, 2015; 52 (3); 287-97
20. CMS Local Coverage Article: Gender Reassignment Services for Gender Dysphoria (Article ID A53793). 04/27/17. https://www.cms.gov/medicare-coverage-database/details/article-details.aspx?articleId=53793&ver=12&ContrId=374&ContrVer=1&CntrctrSelected=374*1&Date=&DocID=A53793&bc=hAAAAAaAEAAAAA%3d%3d&
21. Facial gender confirmation surgery—review of the literature and recommendations for Version 8 of the **WPATH** Standards of Care. Berli, Jens U.; Capitán, Luis; Simon, Daniel; Bluebond-Langner, Rachel; Plemons, Eric; Morrison, Shane D.; *International Journal of Transgenderism*, Jul-Sep2017; 18(3): 264-270. 7p. (Article - research, tables/charts) ISSN: 1553-2739, Database: CINAHL with Full Text
22. Centers for Medicare and Medicaid Services (CMS). Decision Memo for Gender Dysphoria and Gender Reassignment Surgery (CAG-00446N). Date: August 30, 2016. Accessed 04/09/2019. <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=282&bc=AAAAAAAAAAQAAA%3d%3d&>
23. State of Maryland. Maryland Insurance Administration. Maryland Insurance Article. §15 15-810.1 [Coverage](#) for Fertility Preservation Procedures for Iatrogenic Infertility. Accessed 06.21.2019 <https://msa.maryland.gov/megafile/msa/speccol/sc5300/sc5339/000113/000000/000928/unrestricted/20051558e.pdf>



24. Reisner S, Poteat, T Keatley J, Cabral M, Mothopeng T, Dunham E, Holland CE, Max R, and Baral S. Global Health Burden and Needs of Transgender Populations: A Review. *Lancet*. 2016 Jul 23; 388(10042): 412–436. Published online 2016 Jun 17. doi: 10.1016/S0140-6736(16)00684-X. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035595/pdf/nihms-814325.pdf>
25. Nobili, A, Glazebrook, C and Arcelus, J Quality of life of treatment-seeking transgender adults: A systematic review and meta-analysis. *Rev Endocr Metab Disord*. 2018; 19(3): 199–220. Published online 2018 Aug 18. doi: 10.1007/s11154-018-9459-y https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6223813/pdf/11154_2018_Article_9459.pdf
26. Witcomb GL, Bouman WP, Claes L, Brewin N, Crawford JR, Arcelus J. Levels of depression in transgender people and its predictors: Results of a large, matched control study with transgender people accessing clinical services. *J Affect Disord*. 2018 Aug 1; 235:308-315. doi: 10.1016/j.jad.2018.02.051. Epub 2018 Feb 17. https://www.clinicalkey.com/service/content/pdf/watermarked/1-s2.0-S0165032717324400.pdf?locale=en_US&searchIndex=
27. Fernández-Rouco N, Carcedo RJ, López F, Orgaz MB. Mental Health and Proximal Stressors in Transgender Men and Women. *J Clin Med*. 2019 Mar 25;8(3). pii: E413. doi: 10.3390/jcm8030413. PMID:30934613. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463264/pdf/jcm-08-00413.pdf>
28. Fontenot HB, Cahill SR, Wang T, Geffen S, White BP, Reisner S, Conron K, Harper CR, Johns MM, Avripas SA, Michaels S, Dunville R. [Transgender Youth Experiences and Perspectives Related to HIV Preventive Services](#). *Pediatrics*. 2020 Apr;145(4). pii: e20192204. doi: 10.1542/peds.2019-2204. Epub 2020 Mar 17. <https://pediatrics.aappublications.org/content/145/4/e20192204>
29. Ristori, J., Cocchetti, C., Romani, A., Mazzoli, F., Vignozzi, L., Maggi, M., & Fisher, A. D. (2020). Brain Sex Differences Related to Gender Identity Development: Genes or hormones?. *International journal of molecular sciences*, 21(6), 2123. <https://doi.org/10.3390/ijms21062123>
30. Carmichael, P., Butler, G., Masic, U., Cole, T. J., De Stavola, B. L., Davidson, S., Skageberg, E. M., Khadr, S., & Viner, R. M. (2021). Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK. *PloS one*, 16(2), e0243894. <https://doi.org/10.1371/journal.pone.0243894>
31. Meyer, G., Boczek, U., & Bojunga, J. (2020). Hormonal Gender Reassignment Treatment for Gender Dysphoria. *Deutsches Ärzteblatt International*, 117(43), 725–732. <https://doi.org/10.3238/arztebl.2020.0725>.
32. Gürbüz, F., Alkan, M., Çelik, G., Bişgin, A., Çekin, N., Ünal, İ., Topaloğlu, A. K., Zorludemir, Ü., Avcı, A., & Yüksel, B. (2020). Gender Identity and Assignment Recommendations in Disorders of Sex Development Patients: 20 Years' Experience and Challenges. *Journal of clinical research in pediatric endocrinology*, 12(4), 347–357. <https://doi.org/10.4274/jcrpe.galenos.2020.2020.0009>
33. Matthys, I., Defreyne, J., Elaut, E., Fisher, A. D., Kreukels, B., Staphorsius, A., Den Heijer, M., & T'Sjoen, G. (2021). Positive and Negative Affect Changes during Gender-Affirming Hormonal Treatment: Results from the European Network for the Investigation of Gender Incongruence (ENIGI). *Journal of clinical medicine*, 10(2), 296. <https://doi.org/10.3390/jcm10020296>
34. Mahfouda, S., Moore, J. K., Sifarikas, A., Hewitt, T., Ganti, U., Lin, A., & Zepf, F. D. (2019). Gender-affirming hormones and surgery in transgender children and adolescents. *The lancet. Diabetes & endocrinology*, 7(6), 484–498. [https://doi.org/10.1016/S2213-8587\(18\)30305-X](https://doi.org/10.1016/S2213-8587(18)30305-X)
35. Becker-Hebly, I., Fahrenkrug, S., Campion, F., Richter-Appelt, H., Schulte-Markwort, M., & Barkmann, C. (2021). Psychosocial health in adolescents and young adults with gender dysphoria before and after



gender-affirming medical interventions: a descriptive study from the Hamburg Gender Identity Service. *European child & adolescent psychiatry*, 30(11), 1755–1767. <https://doi.org/10.1007/s00787-020-01640-2>

36. World Professional Association for Transgender Health, *Position Statement on Medical Necessity of Treatment, Sex Reassignment, and Insurance Coverage in the U.S.A. December 21, 2016.* http://www.wpath.org/site_page.cfm?pk_association_webpage_menu=1352&pk_association_webpage=3947
37. WPATH. Standards of Care for the Health of Transgender and Gender Diverse Transsexual Related Diagnoses in ICD 11. Standards of Care for the Health of Transsexual, Transgender, and Gender Diverse People. The World Professional Association for Transgender Health (WPATH), 8th Version. Sept 2022. Accessed 08/31/23
38. MCG 27th edition. Copyright © 2023. MCG Health, LLC. Gender Affirming Surgery or Procedure. GRG: GG-FMMF (ISC GRG). Accessed 08/31/202
39. Morrison SD, Capitán-Cañadas F, Sánchez-García A, Ludwig DC, Massie JP, Nolan IT, Swanson M, Rodríguez-Conesa M, Friedrich JB, Cederna PS, Bellinga RJ, Simon D, Capitán L, Satterwhite T. Prospective Quality-of-Life Outcomes after Facial Feminization Surgery: An International Multicenter Study. *Plast Reconstr Surg*. 2020 Jun;145(6):1499-1509. doi: 10.1097/PRS.0000000000006837. PMID: 32459779. https://journals.lww.com/plasreconsurg/fulltext/2020/06000/prospective_quality_of_life_outcomes_after_facial.28.aspx
40. Nuyen BA, Qian ZJ, Campbell RD, Erickson-DiRenzo E, Thomas J, Sung CK. Feminization Laryngoplasty: 17-Year Review on Long-Term Outcomes, Safety, and Technique. *Otolaryngol Head Neck Surg*. 2022 Jul;167(1):112-117. doi: 10.1177/01945998211036870. Epub 2021 Aug 17. PMID: 34399638. <https://pubmed.ncbi.nlm.nih.gov/34399638/>
41. Salesky M, Zebolsky AL, Benjamin T, Wulu JA, Park A, Knott PD, Seth R. Gender-Affirming Facial Surgery: Experiences and Outcomes at an Academic Center. *Facial Plast Surg Aesthet Med*. 2022 Jan-Feb;24(1):54-59. doi: 10.1089/fpsam.2021.0060. Epub 2021 Sep 27. PMID: 34569822. [https://pubmed.ncbi.nlm.nih.gov/34569822/#:~:text=Mean%20hospital%20stay%20after%20first,and%20medical%20complications%20\(6%25\).](https://pubmed.ncbi.nlm.nih.gov/34569822/#:~:text=Mean%20hospital%20stay%20after%20first,and%20medical%20complications%20(6%25).)
42. Kamran, R., Jackman, L., Laws, A., Stepney, M., Harrison, C., Jain, A., & Rodrigues, J. (2024). Developing feasible and acceptable strategies for integrating the use of patient-reported outcome measures (PROMs) in gender-affirming care: An implementation study. *PLoS one*, 19(4), e0301922. <https://doi.org/10.1371/journal.pone.0301922>
43. Brown, J., Pfeiffer, R. M., Shrewsbury, D., O'Callaghan, S., Berner, A. M., Gadalla, S. M., Shiels, M. S., & Jackson, S. S. (2023). Prevalence of cancer risk factors among transgender and gender diverse individuals: a cross-sectional analysis using UK primary care data. *The British journal of general practice : the journal of the Royal College of General Practitioners*, 73(732), e486–e492. <https://doi.org/10.3399/BJGP.2023.0023>
44. Gao, J. L., Sanz, J., Tan, N., King, D. S., Modest, A. M., & Dommasch, E. D. (2023). Androgenetic alopecia incidence in transgender and gender diverse populations: A retrospective comparative cohort study. *Journal of the American Academy of Dermatology*, 89(3), 504–510. <https://doi.org/10.1016/j.jaad.2023.01.037>

45. Lai, A., & Johnson, R. (2023). World professional association for transgender health guidelines: 2022 surgical treatment updates in the standards of care for transgender and gender diverse people. *Neurourology and urodynamics*, 42(5), 900–902. <https://doi.org/10.1002/nau.25099>

Approval History

Date approved by RUMC*	Date filed with the State of Maryland	Date of Implementation (Ten days after filing)
12/19/2012	01/16/2013	01/27/2013
12/26/2013	12/27/2013	01/07/2014
01/02/2015	01/06/2015	01/19/2015
01/31/2016	02/02/2016	02/16/2016

Approval History

Effective June 01, 2016, state filing is no longer required per Maryland House Bill [HB 798](#) – Health Insurance – Reporting

Date Approved by RUMC*	Date of Implementation
01/25/2017	01/25//2017
01/30/2018	01/30/2018
06/27/2018	06/27/2018
06/24/2019	06/24/2019
06/25/2020	06/25/2020
06/24/2021	06/24/2021
11/29/2021	11/29/2021
06/20/2022	06/20/2022
12/28/2022	12/28/2022
11/28/2023	11/28/2023
11/21/2024	11/21/2024

*The Regional Utilization Management Committee received delegated authority in 2011 to review and approve designated Utilization Management and Medical Coverage Policies by the Regional Quality Improvement Committee.

Note: Kaiser Permanente Mid-Atlantic States (KPMAS) include referral and authorization criteria to support primary care and specialty care practitioners, as appropriate, in caring for members with selected conditions. Medical Coverage Policies are not intended or designed as a substitute for the reasonable exercise of independent clinical judgment by a practitioner in any particular set of circumstances for an individual member.

©2024, Kaiser Foundation Health Plan of the Mid-Atlantic States, Inc.
 ©2024 Mid-Atlantic Permanente Medical Group, P.C.